It’s not down on any map.

KRAS(C12C) has been the Moby Dick of many a basic scientist in oncology. One problem with the many attempts at blocking its effects is that GDP-activated KRAS(C12C) is drug-insensitive. Where one group discovered a “cryptic groove” to block constituent activation, this group has revealed synergistic EGFR- and aurora kinase signaling pathways that help keep KRAS(C12C) in its active, drug-elusive state. In other words, effectively targeting KRAS may mean effective concurrent blockade of EGFR. | Xue, Nature 2020